Adobe stock photos - JimObesityLilly’s weight loss pill orforglipron me...Eli Lilly, the US market leader in the lucrative diabetes and obesity space, is now challenging its competitor Novo Nordisk in the area of oral GLP-1 receptor agonists. Lilly’s orforglipron has met … more ➔
Calluna Pharma A/SClinical trialsCalluna Pharma starts efficacy test with...Norway-based Calluna Pharma A/S has initiated patient recruitment in late August for its Phase II AURORA trial investigating safety and efficacy of CAL101, a monoclonal antibody with unique mode of action … more ➔
BioArctic ABNeurodegenerationNovartis secures US$30m+ licence option...Following the commercial launch of BioArctic AB’s Alzheimer’s antibody lecanemab, the Swedish company has announced a new deal: it will receive an upfront payment of US$30m, granting the Swiss company … more ➔
Esai PharmaDementiaAlzheimer’s antibody Lecanemab launched...Swedish BioArctic AB’s partner Eisai Pharma has started the European roll-out of their Alzheimer’s antibody lecanemab in Austria that will be followed by the German launch on September 1, 2025. more ➔
EFPIAUS-EU trade conflictUS and EU confirm tariff deal on pharmac...The US and EU have confirmed a trade agreement involving US import tariffs of 15% on prescription medicines. Generics manufacturers will face a maximum tariff of 2.5%. more ➔
MalliaHair growthMallia Aesthetics is about to launch MAL...Germany’s Mallia Aesthetics GmbH has announced the achievement of key regulatory milestones in preparation for the market launch of its sCD83-based hair growth stimulant, MAL-838, later this year. … more ➔
BioMed XMetabolic DisordersBioMed X and Novo Nordisk collaborate to...Novo Nordisk has entered a collaboration with research institute BioMed X in an effort to regain market position lost to leading competitors in diabetes and obesity treatment. The partnership is focused … more ➔
Anocca ABImmunoncologyAnocca raises €38.4m to advance TCR-T le...Swedish immunoncology specialist Anocca AB has raised SEK440m (€38.36m) ahead of enrolling pancreatic cancer patients in a Phase I umbrella trial evaluating the safety of its T-cell receptor-engineered … more ➔
© EdiMembre/MerckAlternative ProteinMerck and mantro enter the foodtech marketThe laboratory division of Merck KGaA has, in partnership with the German company builder Mantro GmbH, established EdiMembre Inc, a Massachusetts-based company set to deploy Merck’s technologies for … more ➔
adobe stock photos - Tomas RaginaPharmaceutical SupplyTrump delays 250% tariffs on non-U.S. ph...U.S. President Donald Trump’s announcement regarding new tariffs on pharmaceutical goods imported into the United States has been delayed. Despite the President’s threat early last week that a tariff … more ➔
Adobe stock photos - Jim
Calluna Pharma A/S
BioArctic AB
Esai Pharma
EFPIA
Mallia
BioMed X
Anocca AB
© EdiMembre/Merck
adobe stock photos - Tomas Ragina